Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib
Conditions
Interventions
sitravatinib
Locations
5
United States
Orange County Research Center
Tustin, California, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Nucleus Network
Saint Paul, Minnesota, United States
Texas Liver Institute
Austin, Texas, United States
Start Date
March 12, 2021
Primary Completion Date
July 13, 2022
Completion Date
April 13, 2023
Last Updated
October 23, 2023
NCT07324616
NCT04271488
NCT06952634
NCT06841315
NCT06619054
NCT06813781
Lead Sponsor
Mirati Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions